Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Use of 18F-NaF PET in the staging of skeletal metastases of newly diagnosed, high-risk prostate cancer patients: a nationwide cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Mogensen, Anna Winther ; Petersen, Lars J ; Torp-Pedersen, Christian ; Nørgaard, Mette ; Pank, Marie T ; Zacho, Helle D. / Use of 18F-NaF PET in the staging of skeletal metastases of newly diagnosed, high-risk prostate cancer patients : a nationwide cohort study. I: BMJ Open. 2022 ; Bind 12, Nr. 6. s. e058898.

Bibtex

@article{47a27ac6563344838fd6c60c893c18c7,
title = "Use of 18F-NaF PET in the staging of skeletal metastases of newly diagnosed, high-risk prostate cancer patients: a nationwide cohort study",
abstract = "OBJECTIVE: To determine whether preoperative staging of high-risk prostate cancer with 18F-sodium-fluoride (18F-NaF) positron emission tomography (PET) reduces the risk of skeletal metastases.DESIGN: Nationwide, population-based cohort study using real-world data.SETTING: The study used national health registries, including all sites in Denmark from 2011 to 2018.PARTICIPANTS: Newly diagnosed high-risk prostate cancer patients who underwent radical prostatectomy from 2011 to 2018. Patients were stratified into two groups according to the preoperative imaging modality of either 18F-NaF PET or bone scintigraphy.MAIN OUTCOME MEASURES: The risk of skeletal-related events (SREs) as a proxy for skeletal metastases following radical prostatectomy. The secondary endpoint was overall survival.RESULTS: Between 1 January 2011 and 31 December 2018, 4183 high-risk patients underwent radical prostatectomy. Of these patients, 807 (19.3%) underwent 18F-NaF PET and 2161 (51.7%) underwent bone scintigraphy. The remaining 30% were examined by a different imaging method or did not undergo imaging. Using the inverse probability of treatment weighting to control potential confounding, the HR of experiencing an SRE for patients in the 18F-NaF PET group versus the bone scintigraphy group was 1.15 (95% CI 0.86 to 1.54). The 3-year survival rates were 97.4% (95% CI 96.1 to 98.7) and 97.1% (95% CI 96.4 to 97.9) for patients receiving 18F-NaF PET and bone scintigraphy, respectively.CONCLUSION: Patients with high-risk prostate cancer undergoing preoperative staging with 18F-NaF PET did not display a lower risk of developing SREs after prostatectomy compared with patients undergoing bone scintigraphy. The survival rates were similar between the two groups.",
keywords = "Bone Neoplasms/diagnostic imaging, Cohort Studies, Fluorine Radioisotopes, Humans, Male, Positron-Emission Tomography/methods, Prostatic Neoplasms/diagnostic imaging, Sodium Fluoride, epidemiology, nuclear medicine, urological tumours, oncology",
author = "Mogensen, {Anna Winther} and Petersen, {Lars J} and Christian Torp-Pedersen and Mette N{\o}rgaard and Pank, {Marie T} and Zacho, {Helle D}",
note = "{\textcopyright} Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2022",
month = jun,
day = "15",
doi = "10.1136/bmjopen-2021-058898",
language = "English",
volume = "12",
pages = "e058898",
journal = "BMJ Paediatrics Open ",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "6",

}

RIS

TY - JOUR

T1 - Use of 18F-NaF PET in the staging of skeletal metastases of newly diagnosed, high-risk prostate cancer patients

T2 - a nationwide cohort study

AU - Mogensen, Anna Winther

AU - Petersen, Lars J

AU - Torp-Pedersen, Christian

AU - Nørgaard, Mette

AU - Pank, Marie T

AU - Zacho, Helle D

N1 - © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2022/6/15

Y1 - 2022/6/15

N2 - OBJECTIVE: To determine whether preoperative staging of high-risk prostate cancer with 18F-sodium-fluoride (18F-NaF) positron emission tomography (PET) reduces the risk of skeletal metastases.DESIGN: Nationwide, population-based cohort study using real-world data.SETTING: The study used national health registries, including all sites in Denmark from 2011 to 2018.PARTICIPANTS: Newly diagnosed high-risk prostate cancer patients who underwent radical prostatectomy from 2011 to 2018. Patients were stratified into two groups according to the preoperative imaging modality of either 18F-NaF PET or bone scintigraphy.MAIN OUTCOME MEASURES: The risk of skeletal-related events (SREs) as a proxy for skeletal metastases following radical prostatectomy. The secondary endpoint was overall survival.RESULTS: Between 1 January 2011 and 31 December 2018, 4183 high-risk patients underwent radical prostatectomy. Of these patients, 807 (19.3%) underwent 18F-NaF PET and 2161 (51.7%) underwent bone scintigraphy. The remaining 30% were examined by a different imaging method or did not undergo imaging. Using the inverse probability of treatment weighting to control potential confounding, the HR of experiencing an SRE for patients in the 18F-NaF PET group versus the bone scintigraphy group was 1.15 (95% CI 0.86 to 1.54). The 3-year survival rates were 97.4% (95% CI 96.1 to 98.7) and 97.1% (95% CI 96.4 to 97.9) for patients receiving 18F-NaF PET and bone scintigraphy, respectively.CONCLUSION: Patients with high-risk prostate cancer undergoing preoperative staging with 18F-NaF PET did not display a lower risk of developing SREs after prostatectomy compared with patients undergoing bone scintigraphy. The survival rates were similar between the two groups.

AB - OBJECTIVE: To determine whether preoperative staging of high-risk prostate cancer with 18F-sodium-fluoride (18F-NaF) positron emission tomography (PET) reduces the risk of skeletal metastases.DESIGN: Nationwide, population-based cohort study using real-world data.SETTING: The study used national health registries, including all sites in Denmark from 2011 to 2018.PARTICIPANTS: Newly diagnosed high-risk prostate cancer patients who underwent radical prostatectomy from 2011 to 2018. Patients were stratified into two groups according to the preoperative imaging modality of either 18F-NaF PET or bone scintigraphy.MAIN OUTCOME MEASURES: The risk of skeletal-related events (SREs) as a proxy for skeletal metastases following radical prostatectomy. The secondary endpoint was overall survival.RESULTS: Between 1 January 2011 and 31 December 2018, 4183 high-risk patients underwent radical prostatectomy. Of these patients, 807 (19.3%) underwent 18F-NaF PET and 2161 (51.7%) underwent bone scintigraphy. The remaining 30% were examined by a different imaging method or did not undergo imaging. Using the inverse probability of treatment weighting to control potential confounding, the HR of experiencing an SRE for patients in the 18F-NaF PET group versus the bone scintigraphy group was 1.15 (95% CI 0.86 to 1.54). The 3-year survival rates were 97.4% (95% CI 96.1 to 98.7) and 97.1% (95% CI 96.4 to 97.9) for patients receiving 18F-NaF PET and bone scintigraphy, respectively.CONCLUSION: Patients with high-risk prostate cancer undergoing preoperative staging with 18F-NaF PET did not display a lower risk of developing SREs after prostatectomy compared with patients undergoing bone scintigraphy. The survival rates were similar between the two groups.

KW - Bone Neoplasms/diagnostic imaging

KW - Cohort Studies

KW - Fluorine Radioisotopes

KW - Humans

KW - Male

KW - Positron-Emission Tomography/methods

KW - Prostatic Neoplasms/diagnostic imaging

KW - Sodium Fluoride

KW - epidemiology

KW - nuclear medicine

KW - urological tumours

KW - oncology

UR - http://www.scopus.com/inward/record.url?scp=85132079615&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2021-058898

DO - 10.1136/bmjopen-2021-058898

M3 - Journal article

C2 - 35705343

VL - 12

SP - e058898

JO - BMJ Paediatrics Open

JF - BMJ Paediatrics Open

SN - 2044-6055

IS - 6

M1 - e058898

ER -

ID: 78879724